We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

511 hedge funds and large institutions have $10.4B invested in Neurocrine Biosciences in 2023 Q3 according to their latest regulatory filings, with 90 funds opening new positions, 158 increasing their positions, 198 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 90 | Existing positions closed: 30

30% more call options, than puts

Call options by funds: $71.2M | Put options by funds: $54.7M

19% more capital invested

Capital invested by funds: $8.68B → $10.4B (+$1.69B)

12% more funds holding

Funds holding: 456 → 511 (+55)

0.01% more ownership

Funds ownership: 93.97% → 93.98% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 11 → 11 (0)

20% less repeat investments, than reductions

Existing positions increased: 158 | Existing positions reduced: 198

Holders
511
Holders Change
+55
Holders Change %
+12.06%
% of All Funds
8.11%
Holding in Top 10
11
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
90
Increased
158
Reduced
198
Closed
30
Calls
$71.2M
Puts
$54.7M
Net Calls
+$16.5M
Net Calls Change
+$2.59M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$260M
2
VRS
Virginia Retirement Systems
Virginia
+$48.1M
3
FCM
Farallon Capital Management
California
+$47.2M
4
Millennium Management
Millennium Management
New York
+$44M
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$33.7M

Top Sellers

Rank Fund Capital Flow
1
Amundi
Amundi
France
-$93.2M
2
WP
Woodline Partners
California
-$89.4M
3
Man Group
Man Group
United Kingdom
-$66.4M
4
Citadel Advisors
Citadel Advisors
Florida
-$60M
5
AC
Armistice Capital
New York
-$45.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$1.5B -$11.7M -110,744 -0.8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.08B -$1.15M -10,875 -0.1%
State Street
3
State Street
Massachusetts
$432M -$12.6M -119,992 -3%
BG
4
Bellevue Group
Switzerland
$291M -$3.08M -29,250 -1%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$290M +$260M +2,466,770 +2,215%
Morgan Stanley
6
Morgan Stanley
New York
$216M +$5.9M +56,054 +3%
JP Morgan Chase
7
JP Morgan Chase
New York
$204M -$15.9M -150,637 -8%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$193M -$20.2M -191,790 -10%
Renaissance Technologies
9
Renaissance Technologies
New York
$179M -$5.61M -53,238 -3%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$175M +$3.29M +31,222 +2%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$173M -$5.25M -49,823 -3%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$149M -$7.53M -71,500 -5%
Millennium Management
13
Millennium Management
New York
$143M +$44M +418,008 +49%
RSCM
14
Rock Springs Capital Management
Maryland
$139M -$4.58M -43,500 -3%
DCP
15
DSM Capital Partners
Florida
$138M +$17.2M +163,747 +15%
AC
16
Armistice Capital
New York
$137M -$45.7M -433,635 -26%
DM
17
Deerfield Management
New York
$136M – – –
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$133M -$15.8M -150,178 -11%
Brown Advisory
19
Brown Advisory
Maryland
$123M -$1.08M -10,274 -0.9%
Pictet Asset Management
20
Pictet Asset Management
Switzerland
$117M +$110M +1,043,450 New
American Century Companies
21
American Century Companies
Missouri
$114M -$9.53M -90,523 -8%
B
22
Braidwell
Connecticut
$109M +$3.65M +34,662 +4%
Northern Trust
23
Northern Trust
Illinois
$94.9M -$513K -4,869 -0.6%
Goldman Sachs
24
Goldman Sachs
New York
$88.5M -$3.97M -37,682 -5%
Franklin Resources
25
Franklin Resources
California
$86.2M +$3.99M +37,936 +5%
1
2 3 4 5

NBIX Hedge Fund Activity: Q3 2023 in Review

511 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2023, worth a combined $10.4B — up 19% from $8.68B a quarter earlier.

Buyers outnumbered sellers: 90 funds opened new NBIX positions and 30 closed out — a net gain of 60 holders — while 158 added to existing stakes and 198 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $260M. The largest seller was Amundi, cutting an estimated $93.2M.

  • 511 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2023, up from 456 in Q2 2023.
  • Funds reported $10.4B of Neurocrine Biosciences stock for Q3 2023, up 19% quarter-over-quarter.
  • 90 funds opened new Neurocrine Biosciences positions in Q3 2023 and 30 closed out, a net change of +60 holders.
  • The largest Neurocrine Biosciences buyer in Q3 2023 was Point72 Asset Management, an estimated $260M added.
  • The largest Neurocrine Biosciences seller in Q3 2023 was Amundi, an estimated $93.2M sold.

Based on aggregated 13F filings for Q3 2023.